Tucatinib
Showing 1 - 25 of 59
HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))
Not yet recruiting
- HER2-positive Breast Cancer
- Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
- (no location specified)
Jul 20, 2023
Metastatic Breast Cancer Trial in New York (Tucatinib)
Recruiting
- Metastatic Breast Cancer
- Tucatinib
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 26, 2023
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in
Not yet recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Cetuximab
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 2, 2023
HER2-positive Breast Cancer, LMD Trial (Tucatinib 150 MG, Trastuzumab, Capecitabine)
Not yet recruiting
- HER2-positive Breast Cancer
- LMD
- Tucatinib 150 MG
- +3 more
- (no location specified)
Aug 24, 2023
Breast Cancer Metastatic, Leptomeningeal Metastasis Trial (Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection)
Not yet recruiting
- Breast Cancer Metastatic
- Leptomeningeal Metastasis
- Tucatinib Oral Tablet
- +2 more
- (no location specified)
Mar 23, 2023
Brain Metastases, HER2-positive Breast Cancer Trial (Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine)
Not yet recruiting
- Brain Metastases
- HER2-positive Breast Cancer
- Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
- (no location specified)
Jan 10, 2023
Metastatic Solid Tumor, Brain Metastases Trial in Houston (Trastuzumab emtansine, Tucatinib)
Not yet recruiting
- Metastatic Solid Tumor
- Brain Metastases
- Trastuzumab emtansine
- Tucatinib
-
Houston, TexasM D Anderson Cancer Center
Dec 30, 2022
HER2-positive Metastatic Breast Cancer Trial in Aurora, Madison (Alpelisib, Tucatinib, Fulvestrant)
Recruiting
- HER2-positive Metastatic Breast Cancer
- Alpelisib
- +2 more
-
Aurora, Colorado
- +2 more
Dec 29, 2022
Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma Trial in United States (Trastuzumab,
Recruiting
- Adenocarcinoma of the Rectum
- +4 more
- Trastuzumab
- Tucatinib
-
Basking Ridge, New Jersey
- +6 more
Jan 3, 2023
Breast Cancer Trial (Tucatinib, Eribulin, Trastuzumab)
Not yet recruiting
- Breast Cancer
- Tucatinib
- +2 more
- (no location specified)
Jul 12, 2022
Metastatic HER2+ Advanced Breast Cancer, Breast Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC) Trial in
Recruiting
- Metastatic HER2+ Advanced Breast Cancer
- +3 more
- Tucatinib
-
Harbin, Heilongjiang, China
- +4 more
Nov 15, 2022
Breast Cancer, Brain Metastases, HER2-positive Breast Cancer Trial in Los Angeles (Tucatinib, Pembrolizumab, Trastuzumab)
Withdrawn
- Breast Cancer
- +3 more
- Tucatinib
- +2 more
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Jun 28, 2022
Tucatinib in Locally Advanced or Metastatic HER2-positive Breast
Recruiting
- HER2-positive Breast Cancer
-
Essen, Northrhine-Westphalia, GermanyUniversitätsklinikum Essen, Innere Klinik (Tumorforschung)
May 30, 2022
HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma Trial in Spain (Tucatinib, Trastuzumab,
Not yet recruiting
- HER2-positive Metastatic Breast Cancer
- Locally Advanced HER2 Positive Breast Carcinoma
- Tucatinib
- +2 more
-
Cádiz, Andalucía, Spain
- +17 more
Jan 16, 2023
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma Trial in Scottsdale,
Not yet recruiting
- Metastatic Colon Adenocarcinoma
- +5 more
- Trastuzumab
- +2 more
-
Scottsdale, Arizona
- +2 more
Jan 31, 2023
Breast Cancer Stage IV Trial in Clackamas, Newberg, Portland (Tucatinib)
Recruiting
- Breast Cancer Stage IV
- Tucatinib
-
Clackamas, Oregon
- +3 more
Jan 12, 2022
Breast Cancer, HER2-positive Breast Cancer Trial in Australia (Tucatinib, Pembrolizumab, Trastuzumab)
Not yet recruiting
- Breast Cancer
- HER2-positive Breast Cancer
- Tucatinib
- +3 more
-
Albury, New South Wales, Australia
- +11 more
May 22, 2022
Colorectal Tumors Trial in United States (tucatinib, trastuzumab, bevacizumab)
Recruiting
- Colorectal Neoplasms
- tucatinib
- +7 more
-
Anaheim, California
- +13 more
Aug 15, 2022
Breast Cancer Trial in United States (Tucatinib in Combination with Palbociclib and Letrozole)
Active, not recruiting
- Breast Cancer
- Tucatinib in Combination with Palbociclib and Letrozole
-
Tucson, Arizona
- +5 more
Mar 8, 2022
Metastatic Breast Cancer With a Isolated Brain Progression Trial in France (Tucatinib, Pertuzumab, Trastuzumab)
Recruiting
- Metastatic Breast Cancer With a Isolated Brain Progression
- Tucatinib
- +4 more
-
Angers, France
- +33 more
Aug 10, 2022
Kinase Inhibitor Targeted Therapies
Not yet recruiting
- Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib
- Measurement of drug concentrations
-
Rennes, France
- +2 more
Nov 7, 2022
HER2-positive Gastric Cancer Trial in United States (Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel,
Recruiting
- HER2-positive Gastric Cancer
- Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel
- Cinrebafusp alfa (PRS-343) in combination with tucatinib
-
Santa Barbara, California
- +3 more
Jan 14, 2022